Journal article icon

Journal article

Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis

Abstract:

Background

Eosinophilic granulomatosis with polyangiitis is an eosinophilic vasculitis. Mepolizumab, an anti–interleukin-5 monoclonal antibody, reduces blood eosinophil counts and may have value in the treatment of eosinophilic granulomatosis with polyangiitis.

Methods

In this multicenter, double-blind, parallel-group, phase 3 trial, we randomly assigned participants with relapsing or refractory eosinophilic granulomatosis with polyangiitis who had received treatm...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1056/nejmoa1702079

Authors


Expand authors...
GlaxoSmithKline More from this funder
Publisher:
Massachusetts Medical Society Publisher's website
Journal:
New England Journal of Medicine Journal website
Volume:
376
Issue:
20
Pages:
1921-1932
Publication date:
2017-05-18
Acceptance date:
2017-02-28
DOI:
EISSN:
1533-4406
ISSN:
0028-4793
Pmid:
28514601
Source identifiers:
695712

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP